Kristine Wessels
Medical · Spokane, WANPI 1518354141
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Boston Scientific at 43.7% of the total. Reporting peaked in 2023 at $4,506 and has fallen 72.6% since, to $1,233 in 2025. Among medical clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $68.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Medtronic$3K
- AbbVie$435
- Neurocrine Biosciences, Inc.$384
- Acadia Pharmaceuticals Inc$305
- Amneal Pharmaceuticals LLC$254
- plus $1K from 16 others
What the payments were for
- Travel & lodging$5,57954%
- Food & beverage$4,82946%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 41 | $4,556 |
| Medtronic | 28 | $3,486 |
| AbbVie | 16 | $435 |
| Neurocrine Biosciences, Inc. | 10 | $384 |
| Acadia Pharmaceuticals Inc | 10 | $305 |
| Amneal Pharmaceuticals LLC | 10 | $254 |
| Abbott | 4 | $217 |
| Ipsen Biopharmaceuticals, Inc | 7 | $161 |
| Teva Pharmaceuticals USA, Inc. | 4 | $93 |
| Cala Health, Inc. | 4 | $88 |
| MDD US Operations, LLC | 2 | $68 |
| Merz Pharmaceuticals, LLC | 3 | $66 |
| AstraZeneca | 2 | $47 |
| Novo Nordisk | 2 | $42 |
| Acorda Therapeutics, Inc | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 1 | $35 |
| Kyowa Kirin, Inc. | 2 | $30 |
| Exact Sciences | 1 | $29 |
| Boehringer Ingelheim | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Orphalan Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCEPT PC BRAINSENSE$2,645
- VERCISE$442
- INFINITY$152
- QULIPTA$125
- UBRELVY$125
- ONGENTYS$120
- GENERAL DBS$111
- BIONIC NAVIGATOR$109
- INGREZZA$107
How this compares
$10,425 in reported general payments places this provider in the 95th percentile of 457 medical providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 66 | $315,672 |
| RytaryCarbidopa/Levodopa | 130 | $143,117 |
| AustedoDeutetrabenazine | 13 | $115,891 |
| GocovriAmantadine Hcl | 28 | $78,972 |
| NeuproRotigotine | 32 | $30,243 |
| Nurtec OdtRimegepant Sulfate | 23 | $26,813 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 406 | $24,450 |
| OngentysOpicapone | 35 | $22,088 |
| XadagoSafinamide Mesylate | 15 | $21,991 |
| MyrbetriqMirabegron | 34 | $20,766 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 538 | $15,828 |
| Rasagiline Mesylate | 48 | $14,320 |
| Entacapone | 81 | $12,731 |
| Rivastigmine | 49 | $9,486 |
| RivastigmineRivastigmine Tartrate | 96 | $6,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $305 | $315,67266 claims |
| Amneal Pharmaceuticals LLCRytary | $254 | $143,117130 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $93 | $115,89113 claims |
| MDD US Operations, LLCGocovri | $68 | $78,97228 claims |
| Neurocrine Biosciences, Inc.Ongentys | $384 | $22,08835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 medical providers in Washington.
Other medical in Spokane
- Rebecca JohnsonSpokane$14K
- Julia TaylorSpokane$12K
- Kyle RoblesSpokane$8K
- David BacaSpokane$8K
- Zachary StilesSpokane$7K
- Abigail KlemmeSpokane$7K
- Justin OverhoffSpokane$5K
- Alena IzhokhinaSpokane$4K
- Diana McFarlaneSeattle$95K
- Karissa SecoraTacoma$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.